Homology model-based virtual screening for GPCR ligands using docking and target-biased scoring

Journal of Chemical Information and Modeling

Volumn 48, Issue 5, 2008, Pages 1104-1117

  Radestock, Sebastian ^a,b   Weil, Tanja ^a   Renner, Steffen ^a,c  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIGITAL LIBRARIES;

G-PROTEIN COUPLED RECEPTORS; HOMOLOGY MODELING; INTERACTION PATTERN; LIGAND-RECEPTOR INTERACTIONS; METABOTROPIC GLUTAMATE RECEPTORS; SCORING FUNCTIONS; STRUCTURE ACTIVITY RELATIONSHIPS; VIRTUAL LIBRARIES;

LIGANDS;

G PROTEIN COUPLED RECEPTOR; LIGAND; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 5;

ARTICLE; BIOLOGICAL MODEL; CHEMISTRY; COMPUTER INTERFACE; DRUG ANTAGONISM; DRUG SCREENING; METABOLISM; METHODOLOGY; PROTEIN BINDING; SEQUENCE HOMOLOGY;

DRUG EVALUATION, PRECLINICAL; LIGANDS; MODELS, BIOLOGICAL; PROTEIN BINDING; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, METABOTROPIC GLUTAMATE; SEQUENCE HOMOLOGY, AMINO ACID; USER-COMPUTER INTERFACE;

EID: 45749109114     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci8000265     Document Type: Article

References (103)

1. Hopkins, A. L.; Groom, C. R. The druggable genome. Nat. Rev. Drug Discovery 2002, 1, 727-730.
2. Klabunde, T.; Hessler, G. Drug design strategies for targeting G-protein-coupled receptors. ChemBioChem 2002, 3, 929-944.
3. Schlyer, S.; Horuk, R. I want a new drug: G-protein-coupled receptors in drug development. Drug Discovery Today 2006, 11, 481-493.
4. Swanson, C. J.; Bures, M.; Johnson, M. P.; Linden, A. M.; Monn, J. A.; Schoepp, D. D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat. Rev. Drug Discovery 2005, 4, 131-134.
5. Noeske, T.; Gutcaits, A.; Parsons, C. G.; Weil, T. Allosteric modulation of family 3 GPCRs. QSAR Comb. Sci. 2006, 25, 134-146.
6. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000, 289, 739-745.
7. Teller, D. C.; Okada, T.; Behnke, C. A.; Palczewski, K.; Stenkamp, R. E. Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). Biochemistry 2001, 40, 7761-7772.
8. Shacham, S.; Marantz, Y.; Bar-Haim, S.; Kalid, O.; Warshaviak, D.; Avisar, N.; Inbal, B.; Heifetz, A.; Fichman, M.; Topf, M.; Naor, Z.; Noiman, S.; Becker, O. M. PREDICT modeling and in-silico screening for G-protein coupled receptors. Proteins 2004, 57, 51-86.
9. Becker, O. M.; Shacham, S.; Marantz, Y.; Noiman, S. Modeling the 3D structure of GPCRs: Advances and application to drug discovery. Curr. Opin. Drug Discovery Dev. 2003, 6, 353-361.
10. Trabanino, R. J.; Hall, S. E.; Vaidehi, N.; Floriano, W. B.; Kam, V. W. T.; Goddard, W. A. First principles predictions of the structure and function of G-protein-coupled receptors: Validation for bovine rhodopsin. Biophys. J. 2004, 86, 1904-1921.
11. Vaidehi, N.; Floriano, W. B.; Trabanino, R.; Hall, S. E.; Freddolino, P.; Choi, E. J.; Zamanakos, G.; Goddard, W. A. Prediction of structure and function of G protein-coupled receptors. Proc. Natl. Acad Sci. U.S.A. 2002, 99, 12622-12627.
12. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G. F.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. High-resolution crystal structure of an engineered human beta(2)-adrenergic G protein-coupled receptor. Science 2007, 318, 1258-1265.
13. Bender, A.; Glen, R. C. Molecular similarity: a key technique in molecular informatics. Org. Biomol. Chem. 2004, 2, 3204-3218.
14. Marriott, D. P.; Dougall, I. G.; Meghani, P.; Liu, Y. J.; Flower, D. R. Lead generation using pharmacophore mapping and three-dimensional database searching: Application to muscarinic M-3 receptor antagonists. J. Med. Chem. 1999, 42, 3210-3216.
15. Flohr, S.; Kurz, M.; Kostenis, E.; Brkovich, A.; Foumier, A.; Klabunde, T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J. Med. Chem. 2002, 45, 1799-1805.
16. Renner, S.; Noeske, T.; Parsons, C. G.; Schneider, P.; Weil, T.; Schneider, G. New allosteric modulators of metabotropic glutamate receptor 5 (mGluR5) found by ligand-based virtual screening. ChemBioChem 2005, 6, 620-625.
17. Renner, S.; Hechenberger, M.; Noeske, T.; Bocker, A.; Jatzke, C.; Schmuker, M.; Parsons, C. C.; Weil, T.; Schneider, G. Searching for Drug Scaffolds with 3D Pharmacophores and Neural Network Ensembles. Angew. Chem., Int. Ed. 2007, 46, 5336-5339.
18. Schneider, G.; Schneider, P.; Renner, S. Scaffold-hopping: How far can you jump. QSAR Comb. Sci. 2006, 25, 1162-1171.
19. Zhang, Q.; Muegge, I. Scaffold hopping through virtual screening using 2D and 3D similarity descriptors: Ranking, voting, and consensus scoring. J. Med. Chem. 2006, 49, 1536-1548.
20. Sheridan, R. P. Chemical similarity searches: when is complexity justified. Expert Opin. Drug Discovery 2007, 2, 423-430.
21. Renner, S.; Schneider, G. Scaffold-hopping potential of ligand-based similarity concepts. ChemMedChem 2006, 1, 181-185.
22. Kitchen, D. B.; Decomez, H.; Furr, J. R.; Bajorath, J. Docking and scoring in virtual screening for drug discovery: Methods and applications. Nat. Rev. Drug Discovery 2004, 3, 935-949.
23. Lyne, P. D. Structure-based virtual screening: an overview. Drug Discovery Today 2002, 7, 1047-1055.
24. Congreve, M.; Murray, C. W.; Blundell, T. L. Keynote review: Structural biology and drug discovery. Drug Discovery Today 2005, 10, 895-907.
25. Gohlke, H.; Klebe, G. Approaches to the Description and Prediction of the Binding Affinity of Small-Molecule Ligands to Macromolecular Receptors. Angew. Chem., Int. Ed. 2002, 41, 2644-2676.
26. Evers, A.; Klebe, G. Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. J. Med. Chem. 2004, 47, 5381-5392.
27. Bissantz, C.; Logean, A.; Rognan, D. High-throughput modeling of human G-protein coupled receptors: Amino acid sequence alignment, three-dimensional model building, and receptor library screening. J. Chem. Inf. Comput. Sci. 2004, 44, 1162-1176.
28. Bissantz, C.; Bernard, P.; Hibert, M.; Rognan, D. Protein-based virtual screening of chemical databases. II. Are homology models of G-protein coupled receptors suitable targets. Proteins 2003, 50, 5-25.
29. Becker, O. M.; Marantz, Y.; Shacham, S.; Inbal, B.; Heifetz, A.; Kalid, O.; Bar-Haim, S.; Warshaviak, D.; Fichman, M.; Noiman, S. G protein-coupled receptors: In silico drug discovery in 3D. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 11304-11309.
30. Varady, J.; Wu, X. H.; Fang, X. L.; Min, J.; Hu, Z. J.; Levant, B.; Wang, S. M. Molecular modeling of the three-dimensional structure of dopamine 3 (D-3) subtype receptor: Discovery of novel and potent D-3 ligands through a hybrid pharmacophore- and structure-based database searching approach. J. Med. Chem. 2003, 46, 4311-4392.
31. Hobrath, J. V.; Wang, S. M. Computational elucidation of the structural basis of ligand binding to the dopamine 3 receptor through docking and homology modeling. J. Med. Chem. 2006, 49, 4470-4476.
32. Evers, A.; Klabunde, T. Structure-based drug discovery using GPCR homology modeling: Successful virtual screening for antagonists of the AlphalA adrenergic receptor. J. Med. Chem. 2005, 48, 1088-1097.
33. Evers, A.; Hessler, G.; Matter, H.; Klabunde, T. Virtual screening of biogenic amine-binding G-protein coupled receptors: Comparative evaluation of protein- and ligand-based virtual screening protocols. J. Med. Chem. 2005, 48, 5448-5465.
34. McGovern, S. L.; Shoichet, B. K. Information decay in molecular docking screens against holo, apo, and modeled conformations of enzymes. J. Med. Chem. 2003, 46, 2895-2907.
35. Bindewald, E.; Skolnick, J. A scoring function for docking ligands to low-resolution protein structures. J. Comput. Chem. 2005, 26, 374-383.
36. Evers, A.; Gohlke, H.; Klebe, G. Ligand-supported homology modelling of protein binding sites using knowledge-based potentials. J. Mol. Biol. 2003, 334, 327-345.
37. Seifert, M. H. J.; Kraus, J.; Kramer, B. Virtual high-throughput screening of molecular databases. Curr. Opin. Drug Discovery Dev. 2007, 10, 298-307.
38. Fradera, X.; Mestres, J. Guided docking approaches to structure-based design and screening. Curr. Top. Med. Chem. 2004, 4, 687-700.
39. Jansen, J. M.; Martin, E. J. Target-biased scoring approaches and expert systems in structure-based virtual screening. Curr. Opin. Chem. Biol. 2004, 8, 359-364.
40. Hindle, S. A.; Rarey, M.; Buning, C.; Lengauer, T. Flexible docking under pharmacophore type constraints. J. Comput.-Aided Mol. Des. 2002, 16, 129-149.
41. Fradera, X.; Knegtel, R. M.; Mestres, J. Similarity-driven flexible ligand docking. Proteins 2000, 40, 623-636.
42. Daeyaert, F.; de Jonge, M.; Heeres, J.; Koymans, L.; Lewi, P.; Vinkers, M. H.; Janssen, P. A. J. A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI' s in their binding pockets. Proteins 2004, 54, 526-533.
43. Wu, G. S.; Vieth, M. SDOCKER: A method utilizing existing X-ray structures to improve docking accuracy. J. Med. Chem. 2004, 47, 3142-3148.
44. Radestock, S.; Böhm, M.; Gohlke, H. Improving binding mode predictions by docking into protein-specifically adapted potential fields. J. Med. Chem. 2005, 48, 5466-5479.
45. Renner, S.; Derksen, S.; Radestock, S.; Mòrchen, F. Maximum common binding modes (MCBM): Consensus docking scoring using multiple ligand information and interaction fingerprints. J. Chem. Inf. Model. 2008, 48, 319-332.
46. Deng, Z.; Chuaqui, C.; Singh, J. Structural interaction fingerprint (SIFt): A novel method for analyzing three-dimensional protein-ligand binding interactions.J. Med. Chem. 2004, 47, 337-344.
47. Kelly, M. D.; Mancera, R. L. Expanded interaction fingerprint method for analyzing ligand binding modes in docking and structure-based drug design. J. Chem. Inf. Comput. Sci. 2004, 44, 1942-1951.
48. Mpamhanga, C. P.; Chen, B. N.; McLay, I. M.; Willett, P. Knowledge-based interaction fingerprint scoring: A simple method for improving the effectiveness of fast scoring functions. J. Chem. Inf. Model. 2006, 46, 686-698.
49. Spooren, W. P. J. M.; Gasparini, F.; Salt, T. E.; Kuhn, R. Novel allosteric antagonists shed light on mglu(5) receptors and CNS disorders. Trends Pharmacol. Sci. 2001, 22, 331-337.
50. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 1996, 261, 470-489.
51. Willett, P.; Barnard, J. M.; Downs, G. M. Chemical similarity searching. J. Chem. Inf. Comput. Sci. 1998, 38, 983-996.
52. Malherbe, P.; Kratochwil, N.; Zenner, M. T.; Piussi, J.; Diener, C.; Kratzeisen, C.; Fischer, C.; Porter, R. H. P. Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)-pyridine. Mol. Pharmacol. 2003, 64, 823-832.
53. Pagano, A.; Ruegg, D.; Litschig, S.; Stoehr, N.; Stierlin, C.; Heinrich, M.; Floersheim, P.; Prezeau, L.; Carroll, F.; Pin, J. P.; Cambria, A.; Vranesic, I.; Flor, P. J.; Gasparini, F.; Kuhn, R. The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chrornen-1 alpha-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J. Biol. Chem. 2000, 275, 33750-33758.
54. Malherbe, P.; Kratochwil, N.; Mühlemann, A.; Zenner, M. T.; Fischer, C.; Stahl, M.; Gerber, P. R.; Jaeschke, G.; Porter, R. H. P. Comparison of the binding pockets of two chemically unrelated allosteric antagonists of the mGlu5 receptor and identification of crucial residues involved in the inverse agonism of MPEP. J. Neurochem. 2006, 98, 601-615.
55. Mühlemann, A.; Ward, N. A.; Kratochwil, N.; Diener, C.; Fischer, C.; Stucki, A.; Jaeschke, G.; Malherbe, P.; Porter, R. H. P. Determination of key amino acids implicated in the actions of allosteric modulation by 3,3′-difluorobenzaldazine on rat mGlu5 receptors. Eur. J. Pharmacol. 2006, 529, 95-104.
56. Surgand, J. S.; Rodrigo, J.; Kellenberger, E.; Rognan, D. A , chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors. Proteins 2006, 62, 509-538.
57. Kratochwil, N. A.; Malherbe, P.; Lindemann, L.; Ebeling, M.; Hoener, M. C.; Muhlemann, A.; Porter, R. H. P.; Stahl, M.; Gerber, P. R. An automated system for the analysis of G protein-coupled receptor transmembrane binding pockets: Alignment, receptor-based pharmacophores, and their application. J. Chem. Inf. Model. 2005, 45, 1324-1336.
58. Huang, D. H.; Poon, S. F.; Chapman, D. F.; Chung, J.; Cramer, M.; Reger, T. S.; Roppe, J. R.; Tehrani, L.; Cosford, N. D. P.; Smith, N. D. 2-{2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl}pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist. Bioorg. Med. Chem. Lett. 2004, 14, 5473-5476.
59. Eastman, B.; Chen, C. X.; Smith, N. D.; Poon, S.; Chung, J.; Reyes-Manalo, G.; Cosford, N. D. P.; Munoz, B. Expedited SAR study of an mGluR5 antagonists: generation of a focused library using a solution-phase Suzuki coupling methodology. Bioorg. Med. Chem. Lett. 2004, 14, 5485-5488.
60. Poon, S. F.; Eastman, B. W.; Chapman, D. F.; Chung, J.; Cramer, M.; Holtz, G.; Cosford, N. D. P.; Smith, N. D. 3-[3-fluoro-5-(5-pyridin-2-yl-2H- tetrazol-2-yl)phenyl]-4-methylpyridine: a highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonist. Bioorg. Med. Chem. Lett. 2004, 14, 5477-5480.
61. Roppe, J.; Smith, N. D.; Huang, D. H.; Tehrani, L.; Wang, B. W.; Anderson, J.; Brodkin, J.; Chung, J.; Jiang, X. H.; King, C.; Munoz, B.; Varney, M. A.; Prasit, P.; Cosford, N. D. P. Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J. Med. Chem. 2004, 47, 4645-4648.
62. Smith, N. D.; Poon, S. F.; Huang, D. H.; Green, M.; King, C.; Tehrani, L.; Roppe, J. R.; Chung, J.; Chapman, D. P.; Cramer, M.; Cosford, N. D. P. Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity. Bioorg. Med. Chem. Lett. 2004, 14, 5481-5484.
63. Varney, M. A.; Cosford, N. D. P.; Jachec, C.; Rao, S. P.; Sacaan, A.; Lin, F. F.; Bleicher, L.; Santori, E. M.; Flor, P. J.; Allgeier, H.; Gasparini, F.; Kuhn, R.; Hess, S. D.; Velicelebi, G.; Johnson, E. C. SIB-1757 and SIB-1893: Selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J. Pharmacol. Exp. Ther. 1999, 290, 170-181.
64. Molecular Operation Environment, Chemical Computing Group, Inc., Montreal, Quebec, Canada, 2006.
65. Noeske, T.; Jirgensons, A.; Starchenkovs, I.; Renner, S.; Jaunzeme, I.; Trifanova, D.; Hechenberger, M.; Bauer, T.; Kauss, V.; Parsons, C. G.; Schneider, G.; Weil, T. Virtual Screening for Selective Allosteric mGluRl Antagonists and Structure-Activity Relationship Investigations for Coumarine Derivatives. ChemMedChem 2007, 1763-1773.
66. Vanejevs, M.; Jatzke, C.; Renner, S.; Müller, S.; Hechenberger, M.; Bauer, T.; Klochkova, A.; Pyatkin, I.; Kazyulkin, D.; Aksenova, E.; Shulepin, S.; Timonina, O.; Haasis, A.; Gutcaits, A.; Parson, C. G.; Kauss, V.; Weil, T. Positive and Negative Modulation of Group I Metabotropic Glutamate Receptors. J. Med. Chem. 2007, 57, 634-647.
67. Sybyl Molecular Modeling Software, 7.2; Tripos Inc., St. Louis, MO, 2006.
68. Ballesteros, J. A.; Shi, L.; Javitch, J. A. Structural mimicry in G protein-coupled receptors: Implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol. Pharmacol. 2001, 60, 1-19.
69. Alagille, D.; Baldwin, R. M.; Roth, B. L.; Wroblewski, J. T.; Grajkowska, E.; Tamagnan, G. D. Functionalization at position 3 of the phenyl ring of the potent mGluR5 noncompetitive antagonists MPEP. Bioorg. Med. Chem. Lett. 2005, 15, 945-949.
70. Bonnefous, C.; Vernier, J. M.; Hutchinson, J. H.; Chung, J.; Reyes-Manalo, G.; Kamenecka, T. Dipyridyl amides: potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 1197-1200.
71. Cosford, N. D. P.; Tehrani, L.; Roppe, J.; Schweiger, E.; Smith, N. D.; Anderson, J.; Bristow, L.; Brodkin, J.; Jiang, X. H.; McDonald, I.; Rao, S.; Washburn, M.; Varney, M. A. 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine: A potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J. Med. Chem. 2003, 46, 204-206.
72. Iso, Y.; Grajkowska, E.; Wroblewski, J. T.; Davis, J.; Goeders, N. E.; Johnson, K. M.; Sanker, S.; Roth, B. L.; Tueckmantel, W.; Kozikowski, A. P. Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl]pyridine analogues as potent, noncompetitive metabotropic glutamate receptor subtype 5 antagonists; Search for cocaine medications. J. Med. Chem. 2006, 49, 1080-1100.
73. Roppe, J. R.; Wang, B. W.; Huang, D. H.; Tehrani, L.; Kamenecka, T.; Schweiger, E. J.; Anderson, J. J.; Brodkin, J.; Jiang, X. H.; Cramer, M.; Chung, J.; Reyes-Manalo, G.; Munoz, B.; Cosford, N. D. P. 5-[(2-methyl-1,3-thiazol-4- yl)ethynyl]-2,3′-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist with anxiolytic activity. Bioorg. Med. Chem. Lett. 2004, 14, 3993-3996.
74. Wallberg, A.; Nilsson, K.; Osterlund, K.; Peterson, A.; EIg, S.; Raboisson, P.; Bauer, U.; Hammerland, L. G.; Mattsson, J. P. Phenyl ureas of creatinine as mGluR5 antagonists. A structure-activity relationship study of fenobam analogues. Bioorg. Med. Chem. Lett. 2006, 16, 1142-1145.
75. Wang, B. W.; Vernier, J. M.; Rao, S.; Chung, J.; Anderson, J. J.; Brodkin, J. D.; Jiang, X. H.; Gardner, M. F.; Yang, X. Q.; Munoz, B. Discovery of novel modulators of metabotropic glutamate receptor subtype-5. Bioorg. Med. Chem. 2004, 12, 17-21.
76. Hammerland, L. G.; Johansson, M.; Malmstrom, J.; Mattsson, J. P.; Minidis, A. B. E.; Nilsson, K.; Peterson, A.; Wensbo, D.; Wallberg, A.; Osterlund, K. Structure-activity relationship of thiopyrimidines as mGluR5 antagonists. Bioorg. Med. Chem. Lett. 2006, 16, 2467-2469.
77. Arora, J.; Edwards, L.; Isaac, M.; Kers, A.; Staaf, K.; Slassi, A.; Stefanac, T.; Wensbo, D.; Xin, T.; Holm, B. Synthesis of polyheterocyclic compounds as metabotropic glutamate receptor antagonists. WO2005080386, 2005.
78. Edwards, L.; Isaac, M.; Johansson, M.; Malmberg, J.; Minidis, A.; Staaf, K.; Slassi, A.; Wensbo, D. Preparation of triazoles as mGluR5 metabotropic glutamate receptor antagonists. WO2005080379, 2005.
79. Johansson, M.; Minidis, A.; Staaf, K.; Wensbo, D.; McLeod, D.; Edwards, L.; Isaac, M.; O'Brien, A.; Slassi, A.; Xin, T. Preparation of tetrazole compounds and their use as metabotropic glutamate receptor antagonists. WO2005080356, 2005.
80. Johansson, M.; Wensbo, D.; Minidis, A.; Staaf, K.; Kers, A.; Edwards, L.; Isaac, M.; Stefanac, T.; Slassi, A.; McLeod, D. Preparation of heterocyclic-fused 1,3-diazenes and analogs as metabotropic glutamate receptor antagonists. WO2005080397, 2005.
81. Wensbo, D.; Edwards, L.; Isaac, M.; McLeod, D. A.; Slassi, A.; Xin, T.; Stormann, T. M. Fluoro-, chloro- and cyano-pyridin-2-yl-tetrazoles as ligands of the metabotropic glutamate receptor 5. WO2005066155, 2005.
82. Li, C. L.; Xu, L; Wolan, D. W.; Wilson, I. A.; Olson, A. J. Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identify novel nonfolate inhibitors. J. Med. Chem. 2004, 47, 6681-6690.
83. Seifert, M. H. J. Assessing the discriminatory power of scoring functions for virtual screening. J. Chem. Inf. Model. 2006, 46, 1456-1465.
84. Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 2004, 47, 1750-1759.
85. Yang, Y.; Dickinson, C.; Haskell-Luevano, C.; Gantz, I. Molecular basis for the interaction of [Nle4,D-Phe7]melanocyte stimulating hormone with the human melanocortin-1 receptor. J. Biol. Chem. 1997, 272, 23000-23010.
86. Betz, S. F.; Reinhart, G. J.; Lio, F. M.; Chen, C.; Struthers, R. S. Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor. J. Med. Chem. 2006, 49, 637-647.
87. Gao, Z. G.; Chen, A.; Barak, D.; Kim, S. K.; Muller, C. E.; Jacobson, K. A. Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor. J. Biol. Chem. 2002, 277, 19056-19063.
88. Malherbe, P.; Kratochwil, N.; Knoflach, F.; Zenner, M. T.; Kew, J. N. C.; Kratzeisen, C.; Maerki, H. P.; Adam, G.; Mutel, V. Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor. J. Biol. Chem. 2003, 278, 8340-8347.
89. Litschig, S.; Gasparini, F.; Rueegg, D.; Stoehr, N.; Flor, P. J.; Vranesic, I.; Prezeau, L.; Pin, J. P.; Thomsen, C.; Kuhn, R. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol. Pharmacol. 1999, 55, 453-461.
90. Petrel, C.; Kessler, A.; Dauban, P.; Dodd, R. H.; Rognan, D.; Ruat, M. Positive and negative allosteric modulators of the Ca2+-sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain. J. Biol. Chem. 2004, 279, 18990-18997.
91. Petrel, C.; Kessler, A.; Maslah, F.; Dauban, P.; Dodd, R. H.; Rognan, D.; Ruat, M. Modeling and mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator of the extracellular Ca2+-sensing receptor. J. Biol. Chem. 2003, 278, 49487-49494.
92. Miedlich, S. U.; Gama, L.; Seuwen, K.; Wolf, R. M.; Breitwieser, G. E. Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site. J. Biol. Chem. 2004, 279, 7254-7263.
93. Jiang, P. H.; Cui, M.; Zhao, B. H.; Liu, Z.; Snyder, L. A.; Benard, L. M. J.; Osman, R.; Margolskee, R. F.; Max, M. Lactisole interacts with the transmembrane domains of human T1R3 to inhibit sweet taste. J. Biol. Chem. 2005, 280, 15238-15246.
94. Jiang, P. H.; Cui, M.; Zhao, B. H.; Snyder, L. A.; Benard, L. M. J.; Osman, R.; Max, M.; Margolskee, R. F. Identification of the cyclamate interaction site within the transmembrane domain of the human sweet taste receptor subunit T1R3. J. Biol. Chem. 2005, 280, 34296-34305.
95. Verdonk, M. L.; Berdini, V.; Hartshorn, M. J.; Mooij, W. T. M.; Murray, C. W.; Taylor, R. D.; Watson, P. Virtual screening using protein-ligand docking: Avoiding artificial enrichment. J. Chem. Inf. Comput. Sci. 2004, 44, 793-806.
96. Ferrara, P.; Gohlke, H.; Price, D. J.; Klebe, G.; Brooks, C. L. Assessing scoring functions for protein-ligand interactions. J. Med. Chem. 2004, 47, 3032-3047.
97. Perola, E.; Walters, W. P.; Charifson, P. S. A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance. Proteins 2004, 56, 235-249.
98. Cole, J. C.; Murray, C. W.; Nissink, J. W. M.; Taylor, R. D.; Taylor, R. Comparing protein-ligand docking programs is difficult. Proteins 2005, 60, 325-332.
99. Xing, L.; Hodgkin, E.; Liu, Q.; Sedlock, D. Evaluation and application of multiple scoring functions for a virtual screening experiment. J. Comput.-Aided Mol. Des. 2004, 18, 333-344.
100. Muegge, I.; Martin, Y. C.; Hajduk, P. J.; Fesik, S. W. Evaluation of PMF scoring in docking weak ligands to the FK506 binding protein. J. Med. Chem. 1999, 42, 2498-2503.
101. Unity Chemcial Information Software, Tripos Inc., St. Louis, MO.
102. Daylight Chemical Information Software, Daylight Chemical Information Systems, Inc., Mission Viejo, CA.
103. MACCS II, Molecular Design Ltd., San Leandro, CA.